Humana Inc. (NYSE:HUM) Shares Bought by Austin Asset Management Co Inc

Austin Asset Management Co Inc increased its position in Humana Inc. (NYSE:HUM) by 7.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,081 shares of the insurance provider’s stock after buying an additional 78 shares during the quarter. Austin Asset Management Co Inc’s holdings in Humana were worth $274,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Creative Financial Designs Inc. ADV boosted its position in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in Humana during the third quarter worth approximately $31,000. Your Advocates Ltd. LLP grew its position in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the last quarter. Atwood & Palmer Inc. increased its holdings in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares in the last quarter. Finally, LRI Investments LLC lifted its position in shares of Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after acquiring an additional 143 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Insiders Place Their Bets

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.29% of the company’s stock.

Humana Trading Down 2.0 %

NYSE:HUM opened at $274.06 on Friday. The company has a market capitalization of $33.00 billion, a P/E ratio of 24.27, a P/E/G ratio of 2.21 and a beta of 0.56. The stock’s 50 day moving average price is $274.66 and its 200 day moving average price is $299.52. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on HUM shares. TD Cowen boosted their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Truist Financial upped their price objective on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Wells Fargo & Company dropped their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Barclays upped their price target on shares of Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 22nd. Finally, KeyCorp assumed coverage on shares of Humana in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. Nineteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $297.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.